Efficacy and Safety of Accelerated Versus Standard Hepatitis B vaccination regimen among End Stage Renal Disease patients
Phase 3
- Conditions
- HBV immunization in End Stage Renal Disease
- Registration Number
- TCTR20210327001
- Lead Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 132
Inclusion Criteria
ESRD patients
Undetectable AntiHbS
Exclusion Criteria
History of allergic adverse effects with others vaccine
Patients with immunosuppressive drugs
AntiHIV positive
Anti HbC positive
Recent Tetanus-diptheria(Td) vaccine
Refusal to give inform consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Seroconversion rate at 3 month at 3 month after the first dose vaccination Rate
- Secondary Outcome Measures
Name Time Method Seroconversion rate at 7,12 month at 7,12 months after the first dose vaccination rate,AntiHbS GMT titer at 3,7,and 12 month at 3,7, and 12 months after the first dose vaccination numerical value,Compliance at 7 months after the first dose vaccination rate,Adverse reaction at 12 month after the first dose vaccination rate